DE69838249D1 - Anti-apo-2 antikörper - Google Patents

Anti-apo-2 antikörper

Info

Publication number
DE69838249D1
DE69838249D1 DE69838249T DE69838249T DE69838249D1 DE 69838249 D1 DE69838249 D1 DE 69838249D1 DE 69838249 T DE69838249 T DE 69838249T DE 69838249 T DE69838249 T DE 69838249T DE 69838249 D1 DE69838249 D1 DE 69838249D1
Authority
DE
Germany
Prior art keywords
apo
antibodies
chimeras
nucleic acid
acid encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838249T
Other languages
English (en)
Other versions
DE69838249T2 (de
DE69838249T3 (de
Inventor
Avi J Ashkenazi
Camellia W Adams
Anan Chuntharapai
Kyung Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26693808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69838249(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69838249D1 publication Critical patent/DE69838249D1/de
Publication of DE69838249T2 publication Critical patent/DE69838249T2/de
Application granted granted Critical
Publication of DE69838249T3 publication Critical patent/DE69838249T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69838249T 1997-05-15 1998-05-14 Anti-apo-2 antikörper Expired - Lifetime DE69838249T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85721697A 1997-05-15 1997-05-15
US857216 1997-05-15
US2074698A 1998-02-09 1998-02-09
US20746 1998-02-09
EP98926036A EP0981618B2 (de) 1997-05-15 1998-05-14 Anti-apo-2 antikörper
PCT/US1998/009704 WO1998051793A1 (en) 1997-05-15 1998-05-14 Apo-2 RECEPTOR

Publications (3)

Publication Number Publication Date
DE69838249D1 true DE69838249D1 (de) 2007-09-27
DE69838249T2 DE69838249T2 (de) 2008-05-15
DE69838249T3 DE69838249T3 (de) 2012-01-19

Family

ID=26693808

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838249T Expired - Lifetime DE69838249T3 (de) 1997-05-15 1998-05-14 Anti-apo-2 antikörper

Country Status (13)

Country Link
US (1) US20030017161A1 (de)
EP (2) EP0981618B2 (de)
JP (3) JP2001511653A (de)
AT (2) ATE516354T1 (de)
CA (1) CA2287911C (de)
CY (1) CY1106966T1 (de)
DE (1) DE69838249T3 (de)
DK (2) DK1860187T3 (de)
ES (1) ES2293682T5 (de)
HK (1) HK1109423A1 (de)
IL (1) IL132067A0 (de)
PT (2) PT1860187E (de)
WO (1) WO1998051793A1 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
DK0970213T3 (da) 1997-03-17 2007-05-21 Human Genome Sciences Inc Dödsdomæneholdig receptor
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
EP1788086A1 (de) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Rezeptor 5, der eine für den Zelltod verantwortliche Domäne enthält
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
AU9376498A (en) * 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
PT1086138E (pt) * 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
IL146448A0 (en) * 1999-05-28 2002-07-25 Genentech Inc Dr4 antibodies and uses thereof
DE60028971T2 (de) * 1999-06-09 2007-02-08 Genentech, Inc., South San Francisco Apo-2l rezeptor-agonist und cpt-11 synergie-effekt
MXPA01013236A (es) 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
IL148266A0 (en) * 1999-09-15 2002-09-12 Genentech Inc Apo-2 receptor antibodies
NZ520598A (en) * 2000-02-11 2004-04-30 Inst Genetics Llc TRADE molecules and uses related thereto
IL150755A0 (en) 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU4761601A (en) 2000-04-11 2001-10-23 Genentech Inc Multivalent antibodies and uses therefor
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
DK1303293T3 (da) 2000-07-27 2009-03-30 Genentech Inc Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
AU2002256895B2 (en) 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
NZ529359A (en) * 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
EP2192130A1 (de) 2001-07-03 2010-06-02 Genentech, Inc. Humane DR4-Antikörper und deren Anwendungen
US20040186051A1 (en) 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
PT1450847E (pt) 2001-11-13 2011-01-05 Genentech Inc Formulações de ligando de apo2/trail e suas utilizações
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CN1610696A (zh) * 2001-12-20 2005-04-27 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
DE60325334D1 (de) 2002-02-05 2009-01-29 Genentech Inc Proteinaufreinigung
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
EP2500032A1 (de) 2002-06-24 2012-09-19 Genentech, Inc. APO-2-Liganden-/Trailvarianten und Verwendungen dafür
EP1539235A2 (de) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Spezifisch an reg iv bindende antikörper
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2526085A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
EP3722309A1 (de) 2003-07-28 2020-10-14 Genentech, Inc. Verringerung des protein-a-auslaugens während einer affinitätschromatografie
EP1531162A1 (de) * 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
ATE508205T1 (de) 2004-08-06 2011-05-15 Genentech Inc Tests und verfahren unter verwendung von biomarkern
EP2292794A3 (de) 2004-08-06 2011-07-06 Genentech, Inc. DR Antikörper zur pharmazeutischen Verwendung und Verfahren zur Vorhersage der Sensitivität von Zellen gegenüber solchen Antikörpern mittels Biomarkern
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1846034A4 (de) 2005-02-02 2010-11-10 Uab Research Foundation Mittel und verfahren zur reduktion des widerstands gegen apoptose-induzierende todesrezeptor-agonisten
ZA200706246B (en) * 2005-02-02 2008-11-26 Genentech Inc DR5 antibodies and uses thereof
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
RU2409817C2 (ru) 2005-08-16 2011-01-20 Дженентек, Инк. Анализы и способы применения биомаркеров
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
KR101434935B1 (ko) 2005-11-30 2014-10-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101434682B1 (ko) 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP4245766A3 (de) 2007-07-09 2024-01-17 Genentech, Inc. Verhinderung der disulfidbindungsreduktion während der rekombinanten herstellung von polypeptiden
PE20091434A1 (es) 2007-10-30 2009-10-17 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
KR102196883B1 (ko) 2008-08-14 2020-12-30 제넨테크, 인크. 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
EP2684570A1 (de) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Zusammensetzungen und Verfahren zur Prävention des oxidativen Abbaus von Proteinen
JP2012504969A (ja) 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
CN102257122B (zh) 2008-12-16 2015-07-29 Emd密理博公司 搅拌槽反应器及方法
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
EP2400992B1 (de) 2009-02-27 2015-07-22 Genentech, Inc. Verfahren und zusammensetzungen zur kennzeichnung von proteinen
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
EP3736338A1 (de) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Verbesserte proteinreinigung durch eine modifizierte protein-a-elution
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
CN103124564B (zh) 2010-03-22 2016-11-09 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
JP5767207B2 (ja) 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
JP5612761B2 (ja) 2010-05-17 2014-10-22 イー・エム・デイー・ミリポア・コーポレイシヨン 生体分子の精製のための刺激応答性ポリマー
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
BR112012033002B1 (pt) 2010-06-24 2021-10-13 Genentech, Inc Composição aquosa de matéria, método de inibição de agregação induzida por agitação e método de prevenção de oxidação
US20130130317A1 (en) 2010-08-02 2013-05-23 Kyowa Hakko Kirin Co., Ltd Method for producing substance
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
SI2636736T1 (sl) 2010-10-29 2016-09-30 Daiichi Sankyo Company, Limited Novo anti-dr5 protitelesce
DK2653540T3 (en) 2010-12-15 2018-02-05 Inter Univ Research Institute Corporation Research Organization Of Information And Systems PROCEDURE FOR PRODUCING PROTEIN
JP5882913B2 (ja) 2010-12-27 2016-03-09 協和発酵キリン株式会社 培地およびキレート剤を含む水溶液の調製方法
EP2681238A2 (de) 2011-02-28 2014-01-08 Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo Apoptoseinduzierende moleküle und verwendungen davon
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
ES2809211T3 (es) 2011-07-08 2021-03-03 Emd Millipore Corp Filtros de profundidad mejorados para procesos biotecnológicos desechables
ES2697676T3 (es) 2011-12-22 2019-01-25 Hoffmann La Roche Cromatografía de membrana de intercambio iónico
CN109880867A (zh) 2012-03-27 2019-06-14 弗·哈夫曼-拉罗切有限公司 用于重组蛋白质的改进的收获操作
ES2682761T3 (es) 2012-05-18 2018-09-21 Genentech, Inc. Formulaciones de anticuerpos monoclonales de alta concentración
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
PL3166401T3 (pl) 2014-07-09 2021-01-25 F. Hoffmann-La Roche Ag Dostosowanie pH w celu poprawy wyników regeneracji banków komórek po rozmrożeniu
WO2017139485A1 (en) 2016-02-09 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
AU2017242031B2 (en) 2016-03-29 2023-07-27 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
EP3323428A1 (de) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selektive c-flip-hemmer als antikrebsmittel
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
WO2019173499A1 (en) 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
EA202092904A1 (ru) 2018-07-03 2021-04-22 Бристол-Маерс Сквибб Компани Способы получения рекомбинантных белков
US20210380923A1 (en) 2018-10-10 2021-12-09 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
JP7453151B2 (ja) 2018-11-02 2024-03-19 協和キリン株式会社 液体培地の調製方法
CN113660953A (zh) 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
CA3136691A1 (en) 2019-04-12 2020-10-15 Geltor, Inc. Recombinant elastin and production thereof
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
BR112022010757A2 (pt) 2019-12-03 2022-08-16 Shanghai Jiao Tong Univ School Of Medicine Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.
EP3910331A1 (de) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5153118A (en) * 1985-12-17 1992-10-06 Eastern Virginia Medical Authority Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
WO1989003397A1 (en) * 1987-10-16 1989-04-20 Biomedical Systems Limited Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0510691B1 (de) * 1991-04-26 2004-11-03 Osaka Bioscience Institute Für ein menschliches Zelloberflächen-Antigen kodierende DNS
US5216126A (en) * 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
ATE310813T1 (de) * 1995-06-29 2005-12-15 Immunex Corp Apoptosis induzierendes cytokin
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
DK0970213T3 (da) * 1997-03-17 2007-05-21 Human Genome Sciences Inc Dödsdomæneholdig receptor
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CA2287085A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
WO1999009165A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
CN1610696A (zh) * 2001-12-20 2005-04-27 人体基因组科学有限公司 免疫特异性结合trail受体的抗体

Also Published As

Publication number Publication date
ES2293682T5 (es) 2011-11-17
CY1106966T1 (el) 2012-09-26
JP2001511653A (ja) 2001-08-14
EP1860187B1 (de) 2011-07-13
US20030017161A1 (en) 2003-01-23
ATE516354T1 (de) 2011-07-15
EP0981618B2 (de) 2011-08-24
CA2287911A1 (en) 1998-11-19
JP2010075184A (ja) 2010-04-08
IL132067A0 (en) 2001-03-19
PT1860187E (pt) 2011-10-04
ATE370232T1 (de) 2007-09-15
EP0981618A1 (de) 2000-03-01
EP0981618B1 (de) 2007-08-15
AU7796398A (en) 1998-12-08
JP2008148695A (ja) 2008-07-03
HK1109423A1 (en) 2008-06-06
DK0981618T3 (da) 2007-11-26
EP1860187A1 (de) 2007-11-28
PT981618E (pt) 2007-11-23
WO1998051793A1 (en) 1998-11-19
DK0981618T4 (da) 2011-11-21
ES2293682T3 (es) 2008-03-16
DK1860187T3 (da) 2011-10-31
CA2287911C (en) 2014-05-06
DE69838249T2 (de) 2008-05-15
AU740858B2 (en) 2001-11-15
DE69838249T3 (de) 2012-01-19

Similar Documents

Publication Publication Date Title
DE69838249D1 (de) Anti-apo-2 antikörper
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
DE69528061D1 (de) Gereinigte polyporus laccasen und dafür kodierende nukleinsäuren
ATE500323T1 (de) Subtilisin-variante
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
DE69836088D1 (de) Als lerk6 bezeichnetes cytokin
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
ATE291897T1 (de) Verwendung von zusammensetzungen mit stabilisierten enzymen
DE69737747D1 (de) Apo-2 ligand
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
TR199900903T2 (xx) Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DK1009817T3 (da) RTD-receptor
WO2001019861A3 (en) Apo-2 receptor antibodies
SE9602822D0 (sv) New receptor
ATE315092T1 (de) Acetylhydrolase des plättchen aktivierenden faktors, und entsprechendes gen
IL129139A0 (en) Vertebrate smoothened proteins
DK0708831T3 (da) Celletæthedsforstærkende proteintyrosinphosphataser
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 981618

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 981618

Country of ref document: EP

Effective date: 20110824